Clinical trial
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic…
NCT00077181 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077181 |
|---|---|
| Title | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies |
| Official title | A Phase I Study of Triapine in Combination With High Dose Ara-C (Hi-DAC) in Patients With Advanced Hematologic Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8 and 6 more |
| Intervention type | Drug, Other |
| Interventions | cytarabine, triapine, laboratory biomarker analysis |
| Enrollment | 48 |
| Start date | Jan 1, 2004 |
| Primary completion | Jul 1, 2008 |
| First posted | Feb 11, 2004 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: